NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

NCT06203119

RecruitingPhase 1

Sponsor: Peking University Cancer Hospital & Institute

Conditions: Cancer

Interventions: 68Ga-DOTA-BPP, 18F-FDG

Countries: China

This prospective, single-center, open-label study aims to evaluate the safety, biodistribution, and tumor imaging characteristics of the novel ACE1-targeted PET radiotracer 68Ga-DOTA-BPP in patients with confirmed or suspected triple-negative breast cancer (TNBC). Participants will undergo \^68Ga-DOTA-BPP PET/CT and 18F-FDG PET/CT. Visual and semiquantitative imaging analyses will be performed to assess tracer uptake in tumor lesions and normal organs. The relationship between \^68Ga-DOTA-BPP uptake and ACE1 expression will also be explored in participants with available tumor tissue.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria

1. Age 18 to 75 years, inclusive; sex unrestricted.
2. Patients with triple-negative breast cancer (TNBC) or suspected TNBC who are scheduled to undergo pathological tissue biopsy or surgical treatment for the tumor in the near future (within 2 months).
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Estimated life expectancy of ≥12 weeks.
5. Adequate hematologic, coagulation, hepatic, and renal function, defined as follows:

WBC ≥4.0 × 10⁹/L or neutrophil count ≥1.5 × 10⁹/L; PLT ≥100 × 10⁹/L; Hb ≥90 g/L; PT or APTT ≤1.5 × the upper limit of normal (ULN); Total bilirubin ≤1.5 × ULN; ALT and AST ≤2.5 × ULN, or ≤5 × ULN in patients with liver metastases; ALP ≤2.5 × ULN, or ≤4.5 × ULN in patients with bone or liver metastases; BUN ≤1.5 × ULN; Serum creatinine ≤1.5 × ULN. 6:Presence of at least one measurable target lesion according to RECIST version 1.1.

7::Female participants must use effective contraceptive measures during the study period and for 6 months after completion of the study. Male participants must agree to use effective contraceptive measures during the study period and for 6 months after completion of the study.

8:Ability to understand the study procedures, voluntarily sign the informed consent form (ICF), and demonstrate good compliance with study requirements.

9:Baseline assessment established based on \^18F-FDG PET/CT findings. Exclusion Criteria

1. Presence of any of the following conditions: brain metastases, except asymptomatic primary or metastatic brain tumors that do not require treatment; carcinomatous meningitis; myocardial infarction within 6 months prior to enrollment; unstable angina; high risk of uncontrolled arrhythmia; history of coronary artery bypass grafting; cerebrovascular accident within 6 months prior to enrollment; congestive heart failure (NYHA Class III-IV); pulmonary embolism; deep vein thrombosis; concurrent infection requiring intravenous antibiotic treatment within the previous 2 weeks; or receipt of immunosuppressive therapy following organ transplantation.
2. Primary central nervous system tumors.
3. HBV DNA ≥10⁴ copies/mL or ≥2,000 IU/mL.
4. HCV RNA ≥1,000 copies/mL.
5. Positive HIV antibody or syphilis antibody test.
6. History of acute or subacute intestinal obstruction or inflammatory bowel disease.
7. Pregnancy, breastfeeding, or plans to become pregnant during the study period.
8. Known allergy to the investigational drug or any of its excipients.
9. History of substance abuse involving psychiatric medications that cannot be discontinued, or presence of a psychiatric disorder.
10. Inability to lie flat for at least 30 minutes.
11. Known allergy to any component of the imaging agents or antibodies used in the study.
12. Inability to undergo PET/CT imaging.
13. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

Locations (1)

Beijing, Beijing Municipality, China